Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232857 | 1.00 | MAP3K5 (0.67) | MAP3K5AKT1 | |
| SCHEMBL231879 | 0.89 | MAP3K5 (0.68) | MAP3K5AKT1 | |
| SCHEMBL231878 | 0.89 | MAP3K5 (0.68) | MAP3K5AKT1 | |
| SCHEMBL231864 | 0.89 | MAP3K5 (0.67) | MAP3K5AKT1 | |
| SCHEMBL231490 | 0.87 | MAP3K5 (0.65) | MAP3K5AKT1 | |
| SCHEMBL231489 | 0.87 | MAP3K5 (0.65) | MAP3K5AKT1 | |
| SCHEMBL943975 | 0.87 | MAP3K5 (0.84) | MAP3K5 | |
| SCHEMBL233837 | 0.85 | MAP3K5 (0.63) | MAP3K5AKT1 | |
| SCHEMBL232980 | 0.83 | MAP3K5 (0.74) | MAP3K5AKT1 | |
| SCHEMBL27894967 | 0.83 | MAP3K5 (0.57) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588475-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-05-20 | — | — | EP | claimed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2588475-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | claimed |
| WO-2012003387-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | claimed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-RE48150-E1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-2588475-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8927582-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2588475-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003387-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | MAP3K5 11/4885AKT1 212/4885 |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | MAP3K5 11/4885AKT1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.